Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Poseida Therapeutics

Vertex Pharmaceuticals

In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three companies are emerging as pioneers, guiding the world into a new era of therapeutic possibilities.

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

Beam Therapeutics

bluebird bio

Pfizer

In September, Cathie Wood and Ark Invest bought shares of Beam Therapeutics more than a dozen times. Beam Therapeutics is a clinical-stage drugmaker with a unique approach to developing new gene therapies.

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?

Editas Medicine

Editas Medicine and CRISPR Therapeutics are racing towards the same market. It looks like Bluebird Bio is going to be the player to beat in that market.

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics

Kratos Defense & Security Solutions

Twilio

Love her or loathe her, Cathie Wood's magnetic pull on the investment world remains undiminished. Wood has uniquely curated portfolios brimming with disruptive tech firms and ambitious start-ups offering tremendous long-term upside potential.

3 Cathie Wood Stocks Set to Explode Higher

Proto Labs

Unity Software

In an era of rapid technological advancement and groundbreaking innovations, the stock market is constantly abuzz with opportunities and potential pitfalls. Amidst this ever-evolving landscape, three companies stand out as beacons of forward-thinking progress and visionary leadership.

Futurescape: Betting Big on These 3 Next-Gen Tech Stocks

Amazon

Moderna

The number of stocks to choose from could feel overwhelming, but you can narrow down the possibilities by focusing on a couple of key elements. It's important to look at future prospects, the strength of product or service offerings, and potential catalysts ahead.

If I Could Only Buy 3 Stocks in 2023, I'd Pick These

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Chewy

Chewy has a catalyst on the horizon: expansion into an international market with strong growth potential. CRISPR Therapeutics may soon reach a big milestone: the potential approval of its first product.

2 Bargain Growth Stocks to Buy Hand Over Fist

The pharmaceuticals market has taken a bit of a breather in recent weeks after an exhilarating rally earlier this year. But seasoned investors know the ups and downs are part of the natural ebb and flow of the market, and that patience and discipline are rewarded in the long-run.

Don't Miss the Boom: 3 Pharma Stocks Set to Explode Higher

Salesforce

NEXTracker Inc

Palo Alto Networks

UiPath

SoFi Technologies

Block

In the vast equities landscape, hidden gems are waiting to be unearthed. Like diamonds in the rough, these undervalued stocks possess the potential to shine brightly in an investment portfolio.

From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects

ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023.

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Wisdomtree BioRevolution Fund

Intellia Therapeutics

The healthcare sector is disappointing this year. And the ICE Biotechnology Index is even more of a dud on a year-to-date basis.

Multiple Reasons to Bet on Biotech ETF WDNA

Biogen

BioMarin Pharmaceutical

Novartis

Regeneron Pharmaceuticals

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Tesla

Cathie Wood is a visionary investor with an eye toward disruptive new technology. Tesla and Crispr Therapeutics are two of her top holdings that screen as stellar buys right now.

2 Cathie Wood Stocks to Buy Hand Over Fist Right Now

CRISPR Therapeutics has a partnership with Vertex over Exa-Cel, a potentially curative therapy for Sickle Cell Disease and beta thalassemia. The FDA will hold an Advisory Committee meeting before the December 8 decision on Exa-Cel's approval. CEO Sam Kulkarni aims to grow CRISPR Therapeutics into a $25 billion company, comparing it to the rise of RNA therapeutics giants like Alnylam Therapeutics.

CRISPR Therapeutics: CEO Targets $25bn Valuation - Exa-Cel Approval Is First Step

CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and plenty of cash.

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

AbbVie

Amgen

Johnson & Johnson

Eli Lilly

Molina Healthcare

Merck

Novo Nordisk

Seagen

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Flee to Healthcare Stocks if Recession Rears its Head?

Gilead Sciences

Many gene-editing biotechs are developing cures. Curing patients is good.

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know

Advanced Micro Devices

Medtronic

NVIDIA

Before investing in a trend, it's important to make sure it isn't a fad of the moment and instead has staying power. Artificial intelligence and CRISPR gene editing are two popular trends that could be game-changers down the road.

2 Top Trends to Invest $500 In Right Now

Recursion Pharmaceuticals

The timing of upcoming catalysts is a key consideration when comparing biotechs. Recursion Pharmaceuticals may make more revenue soon, but not from its pipeline.

Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics

Medtronic delivers a solid dividend as well as strong returns. CRISPR Therapeutics could soon have its first approved therapy on the market.

3 Top Healthcare Stocks Defying the Bear Market

Medical device giant Medtronic recently lifted its annual earnings guidance. CRISPR Therapeutics is heading for a major milestone: a regulatory decision on what may become its first product.

Better Bull Market Buy: CRISPR vs. Medtronic Stock

Abeona Therapeutics

Vaxart

Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance.

3 Biotech Blockbusters to Turn $5,000 Into $50,000

Bluebird Bio and CRISPR Therapeutics are unprofitable companies focused on gene editing. However, both biotechs are on the verge of winning important regulatory approvals.

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics

I warned investors in June 2022 to be wary about adding Crispr Therapeutics stock. My Sell rating has panned out accordingly as CRSP significantly underperformed the S&P 500. Despite that, CRSP bottomed out in December 2022, in the first sign of a capitulation buy that investors loaded up with conviction. The company is on track for its first approval, which could pave the way toward its commercial entry, bolstering buying sentiments further.

Crispr Therapeutics: The Chance To Load Up Is Finally Here (Technical Analysis)

News for CRISPR Therapeutics Stock (CRSP)